Epigenetic Targets in Synovial Sarcoma: A Mini-Review

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Synovial sarcoma (SS) is a soft tissue sarcoma (STS) comprising 8-10% of STS cases, predominantly affecting young adults (15-35 years).
• SS is characterized by the t(X;18)(p11.2;q11.2) translocation, leading to SS18-SSX fusion proteins.
• The SS18-SSX fusion protein drives SS pathogenesis by altering epigenetic regulators and gene expression.

Purpose of the Study:

• To investigate the roles of SWItch/Sucrose Non-Fermentable (SWI/SNF), Polycomb Repressive Complex 1 (PRC1), and PRC2 in SS pathogenesis.
• To explore the biological rationale for targeting these epigenetic regulators in SS treatment strategies.
• To understand the molecular mechanisms underlying SS development and progression.

Main Methods:

• Analysis of SS pathogenesis driven by SS18-SSX fusion proteins.
• Focus on the functional impact of SS18-SSX on SWI/SNF, PRC1, and PRC2 complexes.
• Review of existing literature on epigenetic rewiring in SS.

Main Results:

• SS18-SSX fusion proteins disrupt SWI/SNF, PRC1, and PRC2 complexes, leading to widespread epigenetic modifications.
• Aberrant gene expression driven by these epigenetic changes contributes to SS development.
• Tumor size, patient age, tumor grade, and genomic complexity are key prognostic factors.

Conclusions:

• SWI/SNF, PRC1, and PRC2 are critical effectors of SS18-SSX-mediated epigenetic alterations.
• Targeting these epigenetic regulators presents a promising therapeutic strategy for SS.
• Further research into these pathways could lead to novel treatments for synovial sarcoma, potentially reducing side effects from current therapies.